Corbus Pharmaceuticals Holdings Inc CRBP experienced a nearly 10% drop in premarket trading after revealing results from its Phase 1/2 trial of CRB-701, a treatment aimed at solid tumors. The data, which will be presented at the ASCO Annual Meeting, indicated a confirmed objective response rate of 42.9% for oropharyngeal squamous cell carcinoma and 34.4% for cervical cancer at a dosage of 3.6 mg/kg. The treatment was reported to be safe, with a low discontinuation rate of 2.8%, down from 6.0% previously. The company plans to initiate a registrational trial for CRB-701 in summer 2026.
The recent drop in CRBP's stock price is largely attributed to the mixed results from its clinical trial for CRB-701. While the response rates for the targeted cancers are promising, the market's reaction suggests that investors may have been hoping for even stronger results or clearer pathways to market approval. The low discontinuation rate is a positive sign, indicating that patients are tolerating the treatment well, which could bode well for future trials.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.